Virtus ETF Advisers LLC Affimed N.V. Transaction History

Virtus ETF Advisers LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.66 - $1.29 $21,747 - $42,506	-32,951 Reduced 27.76%	85,752 $64,000
Q4 2022 Feb 14, 2023	BUY	$1.1 - $2.45 $79,959 - $178,090	72,690 Added 157.98%	118,703 $147,000
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.32 $646 - $1,095	330 Added 0.72%	46,013 $95,000
Q2 2022 Aug 12, 2022	BUY	$2.27 - $4.86 $38,156 - $81,691	16,809 Added 58.22%	45,683 $127,000
Q1 2022 May 16, 2022	SELL	$3.69 - $5.65 $6,324 - $9,684	-1,714 Reduced 5.6%	28,874 $126,000
Q4 2021 Feb 14, 2022	BUY	$5.37 - $7.07 $27,741 - $36,523	5,166 Added 20.32%	30,588 $169,000
Q3 2021 Nov 15, 2021	SELL	$5.54 - $7.51 $7,395 - $10,025	-1,335 Reduced 4.99%	25,422 $157,000
Q2 2021 Aug 10, 2021	SELL	$7.78 - $11.4 $124,145 - $181,909	-15,957 Reduced 37.36%	26,757 $227,000
Q1 2021 May 17, 2021	BUY	$5.12 - $8.48 $3,834 - $6,351	749 Added 1.78%	42,714 $338,000
Q4 2020 Feb 12, 2021	BUY	$3.16 - $7.03 $132,609 - $295,013	41,965 New	41,965 $244,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.